Anterix Inc

ATEX remains in a Stage 2 advancing uptrend with intact higher-highs and a rising 50 DMA, but short-term price has broken below the 9 EMA and 21 EMA amid overbought conditions and declining RSI, indicating unfavorable timing. We will stalk for a pullback into the short-term EMA zone above the rising 50 DMA and await reclaim and acceptance before initiating new long exposure.

• ↑41% YoY revenue growth to $2M in Q4 2026, driven by spectrum deals.
• ↑$71M quarter gain from spectrum monetization; projected cash proceeds now $120M.
• ↓Negative earnings yield indicates challenges in delivering adequate returns.